NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT02859064 2023-12-05Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresSCRI Development Innovations, LLCPhase 2 Terminated6 enrolled 12 charts
NCT04915144 2023-02-21177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsBritish Columbia Cancer AgencyPhase 2 Withdrawn
NCT01327612 2021-02-21Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)AmgenPhase 2 Completed12 enrolled 21 charts
NCT00869050 2016-07-25Capecitabine and Temozolomide for Neuroendocrine CancersColumbia UniversityPhase 2 Completed41 enrolled 9 charts